ADMS News and Press, Adamas Pharmaceuticals Inc. From 10/11/21

Acquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022 Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure Total consideration up to $9...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Thera...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Soci...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock. The restricted stock units vest over t...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the mo...

Image source: The Motley Fool. Adamas Pharmaceuticals Inc (NASDAQ: ADMS) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Adamas Pharmaceuticals Inc (ADMS) Q2 2021 Earnings Call Transcrip...

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Peter Vozzo - Investor Relations Neil McFarlane - Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Chris Prentiss - Chief Financial Officer Adrian Quartel -...

Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering m...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discu...

Adamas Pharmaceuticals ([[ADMS]]) announces the issuance of two patents covering Gocovri (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021.These two patents are the first issued...